Products
Acimtamig Biosimilar Bispecific Antibody (CD16A × CD30) for Research
Cat No.: GMP-Bios-INN-1063
Anti-FCGR3A/CD16/CD16A therapeutic antibody (Pre-made Acimtamig biosimilar,Bispecific (VH-VK-VH'-VL Homodimer)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Acimtamig (development code AFM13) is a bispecific antibody targeting CD16 (FCGR3A) and CD30 (TNFRSF8). It is developed by Affimed Therapeutics for Hodgkin's disease, peripheral T/NK cell lymphoma. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1063-1mg | 1mg | |
| GMP-Bios-INN-1063-10mg | 10mg | |
| GMP-Bios-INN-1063-100mg | 100mg | |
| GMP-Bios-INN-1063-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Acimtamig biosimilar, Bispecific (VH-VK-VH'-VL Homodimer), Anti-FCGR3A/CD16/CD16A;TNFRSF8/CD30 Antibody: Anti-CD16/CD16a/FCGR3A/Low affinity immunoglobulin gamma Fc region receptor III-A therapeutic antibody |
| INN Name | Acimtamig |
| Target | FCGR3A/CD16/CD16A;TNFRSF8/CD30 |
| Format | Bispecific (VH-VK-VH'-VL Homodimer) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 7seg:AB:HL;None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Affimed Therapeutics |
| Conditions Approved | na |
| Conditions Active | Hodgkin's disease;Peripheral T/NK cell lymphoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
